Systemic Nasal Sprays

NEW YORK, June 4, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0870773/Systemic-Nasal-Sprays.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Drug developers and researchers are discovering that the accessibility and vascular structure of the nose make it an attractive route for delivering both small molecule drugs and biologics, systemically as well as across the blood-brain barrier to the CNS. Nasal delivery offers the potential for faster onset of action and less frequent dosing relative to oral drugs. As aging population demographics and managed care initiatives drive growth in home health care and self-administration of drug therapies for chronic conditions such as diabetes, arthritis, and hormone replacement therapy, drug developers are showing increased interest in routes of administration that are patient-friendly and cost-effective. Intranasal administration is well positioned to take advantage of these trends and evolve into a significant role in the future of pharmaceutical development and commercialization. Intranasal delivery will grow at the expense of the predominant drug delivery methods (oral and parenteral), which cannot be readily optimized for the delivery and dosing of a significant portion of biologically derived drug substances.

· Analyzes nasal spray product strategies, technologies and patch development issues

· Provides assessments of intranasal systemic drug products, key design factors and strategic device factors

· Provides market data and forecasts to 2016· Profiles market sector participants, their product development activities and business strategies

The Trend toward Self-AdministrationDemographic ShiftsManaged Care InitiativesGrowth in Home HealthcareTechnology Market DriversCompetitive Landscape

Nasal Delivery Design Factors

AbsorptionBioavailabilityDevice Design ParametersNasal Delivery PharmacokineticsNasal Device Characteristics

Market Factors

Regional RegulationsClinical TrialsIndications and Off-Label PrescribingManaged Care and Payor InitiativesRx-to-OTC Switching

Product Assessments and Market Prospects

Approved Drug ProductsButorphanolDesmopressinFluMistForticalImitrexInstanylLazandaMiacalcinMigranalNicotrolSynarelZomig

Development-Stage Products

Apomorphine

Cytokines

Emitasol

Exenatide

Insulin

Ketamine

Leuprolide

Morphine

Parathyroid

Peptides

Triazolam

Anti-Emetics

Autism

Diabetes

Endocrine Therapy

Immune Therapeutics

Migraine

Metabolic Disorders

Osteoporosis

Pain Management

Parkinson's Disease

Reproductive Medicine

Sleep Disorders

Urology

Forecasts by Region

Market Share Data

More  

Check our  

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED